Patients in the European Union may not be able to receive medicines from the UK post-Brexit if AstraZeneca does not “prepare well” for a no-deal scenario, the company said.
The pharmaceutical giant has its research headquarters in Cambridge and manufactures medicines for treating cancer, heart and lung problems.
Ad Antonisse, the director of market access and external affairs for the company, said it was carrying out tests in both the UK and EU as it prepares for “the strongest Brexit scenario”.
Mr Antonisse, told the Dutch government Brexit-loket site: “If we do not prepare well for Brexit, patients in the EU may no longer be able to receive their medicines. Just because production happens to happen in the United Kingdom.
“Science is simply an international playing field.”
The Anglo-Swedish firm focuses on developing treatments for cancer, cardiovascular and metabolic diseases, and respiratory issues.
“These are serious diseases and you do not want Brexit to have a problem with delivery to the patient,” Mr Antonisse said.
Last month, the new Health and Social Care Secretary said officials were considering working with industry to stockpile drugs, medical devices and supplies in the event of a no-deal Brexit.
Matt Hancock said that he was “confident” that a deal could be reached but said that it was “responsible” to prepare for a range of outcomes.
This includes working up options with industry to stockpile medical supplies if a deal cannot be reached, Mr Hancock told the Health Select Committee on July 24.
He said: “We are working right across Government to ensure that the health sector and the industry are prepared and that people’s health will be safeguarded in the event of a no-deal Brexit.
“This includes the chain of medical supplies, vaccines, medical devices, clinical consumables, blood products.
“And I have asked the department to work up options for stockpiling by industry.
“We are working with industry for the potential need for stockpiling in the event of a no-deal Brexit.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here